Introduction/Background Recent updates to guidelines for the management of ovarian cancer (OC) in Europe and the US include recommendations for BRCA screening and the incorporation of new treatment options. This study sought to quantify regional differences in disease management of OC through analysis of clinical characteristics, treatment patterns and outcomes in Europe and the US.

Methodology This chart review and cross-sectional study of patients actively receiving treatment for OC, collected data through physician-completed, detailed patient record forms. Data were collected from 2496 patients and 340 oncologists/gynecologists in France, Germany, Italy, Spain, the UK (EU5), and the US between December 2017 and March 2018.

Results Stage at initial diagnosis in this sample varied across EU5 countries and the US, with greater proportions of patients diagnosed at Stage III in EU5 (45%) than in the US (30%), and fewer diagnosed at Stage IV (47% in EU5 and 53% in US). The majority of patients were receiving 1L (38% EU5, 45% US) or 2L (54% EU5, 50% US) treatment at the time of data collection. Overall BRCA screening rates were 52% in the EU5 (ranging from 36% in the UK to 64% in Spain) and 46% in the US, with screening rates increasing across line of therapy. Most patients responded to 1L and 2L, although response rates were higher to 1L (76%) than 2L (63%). Bevacizumab use across lines of therapy and PARP inhibitor use in 2L maintenance varied by country.

Conclusion This study documents regional variances in clinical characteristics at initial diagnosis, BRCA screening rates, and regimens used in frontline and frontline maintenance within the EU5, and when comparing EU5 to the US.

Disclosure M.J. Monberg is an employee of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. K. McLaurin and T. Dalvi are employees of AstraZeneca.